A structured peer support intervention for patients undergoing hematopoietic stem cell transplantation
Active Grant Awarded
- Award ID
- R01CA309099
- Recipient
-
Brigham & Womens Hospital Inc. UEI QN6MS4VN7BD1 Part of Partners Healthcare System Incorporated
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $756,755
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 6% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Brigham & Womens Hospital Inc. $756,755 on August 3, 2026, under Grant R01CA309099 in the Cancer Treatment Research program (Assistance Listing 93.395). The grant tests the efficacy of STEPP, a brief, patient-centered, theory-based structured peer support intervention delivered by telephone and compared with minimally enhanced usual care. The intervention, delivered by psychologist-trained hematopoietic stem cell transplantation survivors, targets social isolation, loneliness, depression, and anxiety in patients with hematologic malignancies undergoing transplantation. The period of performance runs through July 31, 2031, and the place of performance is Boston, Massachusetts 02115.
Two subawards dated October 14, 2026 share the work. Fred Hutchinson Cancer Center's site principal investigator, Dr. Stephanie J. Lee, oversees study conduct at that site, supervises research coordination by Gaby Desatnik, ensures data integrity, and participates in statistical analyses and manuscript preparation. H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. serves through Dr. Heather Jim, Co-Investigator and site principal investigator, who administers and oversees the intervention, supervises the site clinical research coordinator and interventionists, oversees data collection, and obtains IRB approval at Moffitt. The STEPP protocol is provided under separate cover.
Description
- Abstract
- Overview: the goal of this study is to test the efficacy of a brief, patient-centered, theoretically-based, telephonedelivered structured peer support intervention (STEPP) compared to minimally enhanced usual care for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). Background: HSCT is a curative treatment for patients with hematologic malignancies. However, most HSCT recipients report that the extremely intensive HSCT regimen and prolonged recovery period exacerbate psychosocial risk factors (e.g., debilitating social isolation) and reduce protective factors (e.g., self-efficacy), contributing to worse health-related outcomes (e.g., elevated depression symptoms). Despite these substantial needs, the few existing psychosocial interventions for HSCT recipients do not directly target risk factors like social isolation and loneliness. Moreover, existing interventions are primarily delivered during or after HSCT hospitalization, missing critical opportunities for early intervention before HSCT, and are often inaccessible to most HSCT recipients due to in-person delivery by specialty-trained clinicians, who are in short supply nationwide. This study addresses psychosocial care gaps for HSCT recipients, aligning with the NCI's mission to advance accessible, cost-effective, and scalable interventions for vulnerable oncology populations. Informed by a psychotherapeutic skill enhancement conceptual framework, we developed the STEPP intervention, which is delivered by psychologist-trained HSCT survivors. Our pilot work has shown feasibility, acceptability, and preliminary efficacy of STEPP for improving depression and anxiety symptoms and quality of life (QOL) in HSCT recipients. Research plan: following the NIH stage model for behavioral intervention development, the next critical step is a large-scale, multi-site randomized clinical trial involving 350 patients preparing to undergo HSCT, to rigorously test the efficacy of STEPP VS. Minimally enhanced usual care for improving psychological distress (e.g., anxiety symptoms), QOL, psychosocial risk factors (e.g., social isolation), and protective factors (e.g., selfefficacy). We will also explore mediators and moderators of STEPP's effects on psychological distress. Environment: this multi-site trial will be conducted at NCI- designated comprehensive cancer centers across the country, including the dana-farber cancer institute, fred hutchinson cancer center, and moffitt cancer center, each of which conducts 400-500 hscts annually. DR. Amonoo and the multi-site research team will leverage their long-term collaborations, extensive expertise in developing and testing psychosocial interventions for patients with hematologic malignancies undergoing HSCT, and robust supportive oncology research infrastructure to successfully execute this trial. Relevance of research: results from this trial will lay the essential groundwork for future scale-up dissemination and implementation trials of our novel and scalable STEPP intervention in clinical practice with vast potential to benefit HSCT and other underserved oncologic populations in healthcare systems nationwide.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. | $256,730 | |
| Fred Hutchinson Cancer Center | $194,280 |
Quick answers
Who received award R01CA309099?
R01CA309099 was awarded to Brigham & Womens Hospital Inc. by National Cancer Institute (National Institutes of Health) on August 3, 2026.
How much is award R01CA309099 worth?
$756,755 has been obligated on R01CA309099.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award